Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TRIB
stocks logo

TRIB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
7.50M
-48.99%
-0.510
-28.57%
10.50M
-33.72%
-0.370
-19.57%
Estimates Revision
The market is revising No Change the revenue expectations for Trinity Biotech plc (TRIB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -14.05%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-14.05%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Trinity Biotech PLC (TRIB.O) is -0.56, compared to its 5-year average forward P/E of 0.71. For a more detailed relative valuation and DCF analysis to assess Trinity Biotech PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.71
Current PE
-0.56
Overvalued PE
8.41
Undervalued PE
-7.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.45
Current PS
0.00
Overvalued PS
0.69
Undervalued PS
0.21
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TRIB News & Events

Events Timeline

(ET)
2025-11-18
09:45:23
Trinity Biotech obtains regulatory clearance for third-party manufacturing.
select
2025-11-14 (ET)
2025-11-14
09:07:42
Trinity Biotech Partners to Enhance Data Analysis for EpiCapture
select
2025-10-27 (ET)
2025-10-27
09:04:16
Trinity highlights Perceptive Advisors' suggestion for debt-to-equity conversion.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-14Newsfilter
Trinity Biotech Partners to Enhance Epigenetic Analysis for EpiCapture Prostate Cancer Test

  • Collaboration Announcement: Trinity Biotech has partnered with a bioinformatics company to enhance the analysis of clinical trial data for its EpiCapture test, a non-invasive liquid biopsy for monitoring prostate cancer progression.

  • Clinical Significance: The EpiCapture test detects DNA methylation patterns linked to high-grade prostate cancer, potentially reducing the need for invasive procedures like biopsies and improving patient care.

  • Market Context: Prostate cancer is the most common non-skin cancer among men in the U.S., with significant economic implications, as diagnosis and treatment costs exceed $10 billion annually.

  • Future Development: Trinity Biotech aims to leverage its diagnostic expertise to advance EpiCapture towards regulatory approval and commercialization, while also expanding its portfolio in the diagnostics and diabetes management sectors.

[object Object]
Preview
8.5
10-27Newsfilter
Trinity Biotech Embraces Perceptive Advisor's Suggestion for Possible Debt-to-Equity Conversion to Enhance Balance Sheet and Foster Growth

  • Trinity Biotech's Debt Conversion Proposal: Trinity Biotech plc announced that its largest investor, Perceptive Advisors, intends to propose a plan to convert part of the company's outstanding debt into equity, which could strengthen its balance sheet and enhance financial flexibility.

  • Focus on Growth and Innovation: The company is focused on developing diabetes management solutions and human diagnostics, including wearable biosensors, and has recently acquired assets from Waveform Technologies to expand its product offerings.

  • Forward-Looking Statements and Risks: The announcement includes forward-looking statements regarding the company's financial position and growth potential, while also highlighting various risks and uncertainties that could impact future operations.

  • About Perceptive Advisors: Perceptive Advisors is a life sciences investment firm with approximately $8 billion in assets, dedicated to supporting advancements in healthcare technologies.

[object Object]
Preview
7.0
09-02Newsfilter
Trinity Biotech Meets Nasdaq Listing Standards Again

  • Regaining Compliance: Trinity Biotech has regained compliance with Nasdaq's minimum bid price and market value requirements after meeting the necessary thresholds for its American Depositary Shares and publicly held shares.

  • Company Overview: Trinity Biotech focuses on human diagnostics and diabetes management solutions, including wearable biosensors, and has recently expanded its product offerings through the acquisition of Waveform Technologies Inc.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Trinity Biotech PLC (TRIB) stock price today?

The current price of TRIB is 0.997 USD — it has decreased -0.3 % in the last trading day.

arrow icon

What is Trinity Biotech PLC (TRIB)'s business?

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

arrow icon

What is the price predicton of TRIB Stock?

Wall Street analysts forecast TRIB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRIB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Trinity Biotech PLC (TRIB)'s revenue for the last quarter?

Trinity Biotech PLC revenue for the last quarter amounts to 15.15M USD, increased 3.24 % YoY.

arrow icon

What is Trinity Biotech PLC (TRIB)'s earnings per share (EPS) for the last quarter?

Trinity Biotech PLC. EPS for the last quarter amounts to -0.02 USD, decreased -90.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Trinity Biotech PLC (TRIB)'s fundamentals?

The market is revising No Change the revenue expectations for Trinity Biotech plc (TRIB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -14.05%.
arrow icon

How many employees does Trinity Biotech PLC (TRIB). have?

Trinity Biotech PLC (TRIB) has 398 emplpoyees as of December 05 2025.

arrow icon

What is Trinity Biotech PLC (TRIB) market cap?

Today TRIB has the market capitalization of 18.58M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free